Investors who purchased shares of ImmunityBio, Inc. (NASDAQ: IBRX) have a deadline of May 26, 2026, to petition the court to be appointed as lead plaintiff in a pending securities class action lawsuit. The lawsuit, filed in the United States District Court for the Central District of California, alleges the company made materially false and misleading statements regarding its business and prospects.
The class action period cited in the lawsuit is from May 23, 2023, to January 3, 2025. The complaint alleges that during this period, ImmunityBio and certain executives failed to disclose adverse facts about the commercial prospects of its drug Anktiva (N-803) in combination with BCG for bladder cancer, and about manufacturing issues at its facilities.
Kaplan Fox & Kilsheimer LLP is one of several law firms publicly announcing the deadline and investigating potential claims on behalf of shareholders. Investors who suffered losses are encouraged to contact the firm before the May 26, 2026, deadline to discuss their rights. The lead plaintiff will act on behalf of all other class members in directing the litigation.
ImmunityBio is a clinical-stage immunotherapy company. The case is pending under the caption Browning v. ImmunityBio, Inc. et al., Case No. 2:25-cv-00765. This information is based on legal notices and court filings related to the ongoing litigation.
